Viewing entries in
News

The Allergic March – Is It Possible to Prevent Allergies and Asthma?

AAT Winter 2016 - The Allergic March_Page_2.jpg
 

Katie Kastan was worried. Her infant daughter Lucy was unusually fussy and having trouble falling asleep. One pediatrician wrote off her concerns as typical new mother paranoia.

Then Katie, who lives in Lino Lakes, Minnesota, noticed Lucy’s skin was red and itchy – eczema.

Lucy was showing signs that suggest early allergic disease.

In young children, allergies often first express themselves as eczema. The skin condition can also be associated with food allergies, ear infections, allergic rhinitis and asthma – the so-called allergic march.

Katie brought Lucy to an allergist for testing after she later showed signs of food allergies. The allergist found Lucy has peanut and dairy allergies. Soon after Katie was found to be allergic to pollen and dogs. “If she gets licked by a dog, she breaks out in hives,” Katie says.

Now age 4, Lucy is experiencing fewer allergic reactions to dogs – instead of progressing to a more severe response.

READ THE FULL ARTICLE from the Allergy and Asthma Network.

Elizabeth Falkner Goes Skin Deep On Atopic Dermatitis

AAT Winter 2016 - Skin Deep_Page_1.jpg

Elizabeth Falkner’s career was just starting to take off. She was in her early 30s, a chef and owner of a trendy San Francisco restaurant, when she began to experience painful, itchy skin rashes and lesions on her legs.

At first Elizabeth chalked it up to irritation from wearing shin guards – she’s an avid soccer player. Then the rashes appeared on her arms and hands.

“It kept getting worse – it was a burning sensation,” she says. “I went to my doctor and was diagnosed with moderate-to-severe atopic dermatitis.”

READ THE FULL ARTICLE from the Allergy Asthma Network.

Sanofi and Regeneron Announce FDA Approval of Dupixent (dupilumab)

Sanofi and Regeneron Pharmaceuticals, Inc has recently announced that the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) Injection, the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.

Read more at Biospectrumasia  

Psoriasis patients have reduced access to efficient treatment method with age

Age plays a huge role when it comes to patients’ access to psoriasis treatment, research shows. Researchers who have examined if patients of varying ages have the same access to the most efficient psoriasis treatment, found that an age increase of 30 years resulted in an average 65 per cent reduction in likelihood of obtaining treatment with biologics.

More at Science Daily

FDA Approves New Ointment for Eczema

Patients aged 2 and older have a new option for treating their mild to moderate eczema (atopic dermatitis). AD, often called eczema, is a chronic condition impacting nearly 18 million children and adults in the United States.  Approximately 90 percent of people living with AD have the mild to moderate form of the condition.

More at DermCast.TV